After meeting with Regeneron's management, BMO Capital believes that the company's EYLEA drug can gain 30%-40% market share in AMD alone and potentially double the AMD opportunity in other indications. The firm maintains a $158 target and Outperform rating.
Yahoo Inc's board has approved a deal to buy blogging and social networking site Tumblr for $1.1 billion in cash, …